2026 PBM Spread Pricing Crackdown: How Employers Are Leveraging Pass-Through and Transparent Models to Reclaim Lost Pharmacy Dollars

When $400,000 Vanishes in the Rebate Fog

A 1,200-employee healthcare system I worked with last year thought it was paying $1.8 million a year for pharmacy benefits through a large PBM. After a full claims audit, the real cost landed closer to $2.2 million once spreads, clawbacks, and obscure rebate terms surfaced. Roughly $400,000 of value had been quietly siphoned off in hidden markups and undisclosed revenue streams. That jolt led to quick action: by 2026 the employer shifted to a transparent pass‑through contract and cut their per‑member‑per‑month pharmacy cost from $128 to $104 within ten months. Real money, back in the plan.

This isn’t some outlier anymore. The current regulatory climate has cornered PBMs that still rely on spread pricing or rebate games. State and federal scrutiny in 2025 and 2026 forced them to defend profit models line by line. Employers, newly armed with broader audit rights and mandated disclosures, are rewriting contracts that finally reveal what every pill, patch, and vial actually costs.

The Regulatory Shift Behind 2026’s Spread Pricing Crackdown

Several trends collided to make 2026 the year PBM transparency went from talking point to survival necessity. By late 2025, nearly two dozen states had already outlawed spread pricing in Medicaid managed care. A year later, many expanded those bans to state‑regulated commercial business, requiring PBMs to show ingredient cost, dispensing fees, and rebate pass‑through details directly to plan sponsors. At the same time, ERISA fiduciary guidance explicitly tied employer accountability to PBM fee reasonableness and disclosure. HR and finance leads suddenly had to treat their pharmacy contracts like 401(k) plans, with documentation ready for auditors.

That pressure clarified what employers had suspected for years. Under spread pricing, PBMs collect more from employers than they pay to pharmacies, pocketing the gap. It’s a model built on misaligned incentives: cutting pharmacy reimbursement while inflating employer costs. Until the 2025 Transparency in Coverage file expansion, those spreads were nearly impossible to measure. Now they can be benchmarked against National Average Drug Acquisition Cost and other public reference rates. The numbers tell the story plainly.

How Employers Are Reclaiming Dollars Through Transparent Contracts

Pass‑through PBM models do one big thing: they end the shell game. Every rebate goes to the plan, and the PBM earns only a fixed administrative fee, usually $3-$8 per member per month. That setup lets employers see every ingredient cost, validated dispensing fee, and rebate amount tied to each claim. But the real advantage isn’t just seeing the data, it’s gaining enough clarity to manage cost drivers without guesswork.

One manufacturer I advised in early 2026, about 500 employees total, replaced a spread‑based contract with an independent pass‑through vendor. Before switching, net spend averaged $121 PMPM, with just 70% of rebates making it back to the plan. After the transition and adding a transparent specialty carve‑out, spending dropped to $98 PMPM in the first plan year, about $276,000 saved. The CFO turned around and funded new HSA contributions with the recovered dollars. That’s how transparency should look in practice: measurable, not theoretical.

But transparency doesn’t guarantee perfection. You still need active oversight. Confirm audit rights for claims and rebates. Make sure the administrative fee actually covers all program services. Watch for hidden revenue sources relabeled as “clinical support” or “data access.” The best move is modeling savings under both spread and pass‑through designs before you switch. For benchmarking PBM models and contract types, visit RxPBM.ai.

2026 Market Reality: Spread Pricing Still Hides in Plain Sight

Even with the crackdown, spread pricing hasn’t vanished. Some PBMs now call it “margin‑based pricing” or “discount guarantees,” bundling costs so employers never see what the pharmacy was paid. Rebates may pass through, but another slice of margin still hides in the network rate. Employers keep losing six‑figure sums without a single line on the invoice showing “spread.”

Here’s a case in point: a 900‑life law firm in the Southeast discovered during an audit that generic drugs, promised at AWP minus 74%, were actually reimbursed to pharmacies at AWP minus 82%. The PBM pocketed the 8% difference, about $180,000 a year, all masked under the discount guarantee. The employer thought they had negotiated a great deal. They hadn’t. Chasing the biggest discount number often means chasing shadows. Spread‑free contracts don’t sound as flashy in marketing decks, but they deliver more predictable costs because the PBM only earns on the service, not the transaction spread. Look, boring transparency beats clever opacity every time.

Making Transparency Work Without Disrupting Employees

The best employer transitions in 2026 blended transparent contracting with minimal member headache. Going pass‑through doesn’t require swapping pharmacies or forcing mail order. It just straightens the money path. When communication focuses on cost clarity rather than network changes, disruption fades to almost nothing.

Plenty of groups now layer real‑time member savings tools on top of transparent PBMs. Linking discount cash‑price data from RxSaver.ai at point of sale helps members see cheaper options instantly. These tools shine on short‑term or acute prescriptions, especially for groups under 2,000 lives where every dollar counts. Employers gain credibility, employees save cash, and the plan’s goodwill multiplies without redesigning the benefit.

And then there’s specialty management. With specialty drugs now around 52% of total pharmacy spend, even minor improvements pay off fast. Steering just a handful of high‑cost patients into manufacturer assistance or copay programs can free hundreds of thousands of dollars. Transparent reconciliation makes those results visible, line by line, proving real value instead of vague cost‑containment slogans.

What’s Next for Employers in a Post‑Spread Market

As employers prepare 2027 RFPs, the PBM landscape will keep splitting: legacy rebate‑driven operators on one side, smaller fully transparent vendors on the other. The Big Three, CVS Caremark, Express Scripts, and OptumRx, are testing hybrid transparency models claiming full rebate pass‑through while quietly retaining administrative spreads. Every employer should press them for ingredient cost reporting, rebate flow proof, and third‑party audit rights. Watch what’s disclosed, not what’s promised.

The 2026 spread‑pricing crackdown didn’t simplify the PBM world, it just leveled the playing field. Employers now hold more bargaining power than ever. Transparent models let even mid‑sized groups work with the same clarity Fortune 100s once had to buy. For HR and finance teams balancing every dollar, the takeaway is simple enough: the only savings that matter are the ones you can actually verify, track, and keep. And that’s where this conversation will keep heading, once people see that transparency isn’t buzz, it’s basic math.